Indications : התוויות

4.1.     Therapeutic indications
Piperacillin/tazobactam is indicated for the treatment of infections caused by susceptible organisms.

Piperacillin/tazobactam in combination with an aminoglycoside is indicated for the treatment of suspected bacterial infections in neutropenic adults and children above 2 years.
Appendicitis complicated by rupture with peritonitis and/or abscess formation in children aged 2-12 years.

Appropriate culture and susceptibility tests should be performed before treatment in order to identify organisms causing infections and to determine their susceptibilities to piperacillin/ tazobactam.
Because of its broad spectrum of activity against Gram-positive and Gram-negative aerobic and anaerobic organisms as listed below, piperacillin/tazobactam is particularly useful in the treatment of mixed infections and in presumptive therapy prior to the availability of the results of sensitivity tests.

Therapy with piperacillin/tazobactam may, however, be initiated before results of such test are known.
Modification of the treatment may be required once these results become available or if there is no clinical response.

In serious infections presumptive therapy with piperacillin/tazobactam may be initiated before susceptibility test results are available.
Piperacillin/tazobactam acts synergistically with aminoglycosides against certain strains of Pseudomonas aeruginosa. Combined therapy has been successful, especially in patients with impaired host defenses. Both drugs should be used in full therapeutic doses. As soon as results of culture and susceptibility test become available, antimicrobial therapy should be adjusted.

To reduce the development of drug-resistant bacteria and maintain the effectiveness of Piperacillin/ Tazobactam Panpharma (piperacillin and tazobactam) injection and other antibacterial drugs, Piperacillin/Tazobactam Panpharma (piperacillin and tazobactam) should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.